GLP-1 drugs have been linked to numerous potential health benefits like treatment of existing conditions including heart ...

On October 3, Amy Kane, 35, who once weighed 300 pounds at her heaviest, garnered 1.7 million views (@amyinhalf) after ...

Australia's S&P/ASX 200 slipped 0.3% to 8,160.00 ... diabetes treatment Mounjaro and weight loss counterpart Zepbound. Also falling was Trump Media & Technology Group, the company behind former Donald ...

Sales of Lilly’s diabetes treatment Mounjaro and weight loss counterpart Zepbound were hurt in the quarter as U.S. pharmaceutical wholesalers whittled inventory they had built up in previous ...

Drugmaker Eli Lilly‘s stock tumbled by 6% after the company missed profit and revenue expectations for Q3 primarily due to ...

Sales of Zepbound and Mounjaro, the name under which the same drug is sold to treat Type 2 diabetes, both fell well short of Wall Street estimates. News Today's news ...

Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...